dual anti-CD19/anti-BAFF-R CAR T-cell therapy (Beckman Research Institute/City of Hope)

N/A

Report date: 2025/03/19 08:58:25

Base Information

Drug Namedual anti-CD19/anti-BAFF-R CAR T-cell therapy (Beckman Research Institute/City of Hope)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-cell activating factor receptor modulatorsB-lymphocyte antigen CD19 modulators

TargetsB-cell activating factor receptorB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBeckman Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesBeckman Research Institute

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A